Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics #00312

Submission Number:
00312
Commenter:
Daniel Winkelmann.Jr
State:
Missouri
Initiative Name:
Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics
I am upset that the DIR are taken off. We hardly make enough to pay for the drug and a small professional fee. It is an insult to us. We cannot judge how much we make. It is hard to stay in business with the PBMs taking almost all rebates. Years ago it was better. Any help to defuse this program would be appreciated. Thanks,